Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy
about
Hepatitis B virus reactivation with a rituximab-containing regimenAntiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)Hepatitis B virus reactivation with rituximab-containing regimenTreatment of rheumatic diseases and hepatitis B virus coinfectionHepatitis B virus management to prevent reactivation after chemotherapy: a review.Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.Management of hepatitis B reactivation in patients receiving cancer chemotherapy.Management of rheumatic disease with comorbid HBV or HCV infection.Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV.Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis.Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders.Antiviral therapies for managing viral hepatitis in lymphoma patients.Hepatitis A to E: what's new?The effect of anticancer therapy on anti-hepatitis B antibody titres in patients with haematological malignancies and solid tumoursComputerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project.Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
P2860
Q26785963-E334C3FC-7688-4248-8F44-8C9CC9E04E1CQ26801716-260F5563-C740-40E1-9C7E-6D764CB321BCQ26830484-8CDFDB23-F26B-4228-9302-EF566648780EQ28084305-DDAF8D1B-7853-42B8-BCEE-C1F159F9E74AQ34397738-C412DABD-75EE-4C00-94D0-DBBECC2CB753Q35037621-A528518C-4A73-4D89-8DA4-D365330409B7Q36220459-34DD5510-98F1-48DC-A30E-E8D02E22C408Q38008173-12B34F7E-349E-4EC3-80D7-970166E20376Q38084182-A34D4076-B9F3-4509-89C6-627491505075Q38218566-D6722803-BD5D-434F-BE9C-D473573597A2Q38375943-9A344E75-66AB-4A35-8A4A-04367912942AQ38397403-4D75BFF3-5D99-4416-A82C-5F4CE4F13D82Q38601007-5FFEFF42-D997-4B6A-9FD7-C419AE8937CAQ38810735-97A40EC4-0F5C-48BA-9ABA-7A8B9173EC15Q38989625-641F4B81-F6FF-4C78-B969-7F6943D1D1CEQ39237214-698DD4FE-82CF-43E0-B781-5ACB98E5B93FQ40727234-26824A9E-0066-45E4-8121-BBFC66ED54F4Q42234350-5FD12FB6-C3A5-4645-AB91-339A4C4B9E4FQ42272307-98D87081-25ED-436E-B412-104B3DAFFD1E
P2860
Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatitis B screening, prophyl ...... f rituximab-based chemotherapy
@en
Hepatitis B screening, prophyl ...... rituximab-based chemotherapy.
@nl
type
label
Hepatitis B screening, prophyl ...... f rituximab-based chemotherapy
@en
Hepatitis B screening, prophyl ...... rituximab-based chemotherapy.
@nl
prefLabel
Hepatitis B screening, prophyl ...... f rituximab-based chemotherapy
@en
Hepatitis B screening, prophyl ...... rituximab-based chemotherapy.
@nl
P2093
P2860
P1433
P1476
Hepatitis B screening, prophyl ...... f rituximab-based chemotherapy
@en
P2093
Jae Young Jang
Jorge Méndez-Navarro
Kathleen E Corey
Lydia L Barlow
Run-Xuan Shao
Steven L McAfee
P2860
P304
P356
10.1111/J.1478-3231.2010.02332.X
P577
2010-08-25T00:00:00Z